Merck & Co. (MRK)
(Delayed Data from NYSE)
$104.23 USD
+0.25 (0.24%)
Updated Oct 28, 2024 04:02 PM ET
After-Market: $104.26 +0.03 (0.03%) 6:52 PM ET
3-Hold of 5 3
B Value C Growth F Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$104.23 USD
+0.25 (0.24%)
Updated Oct 28, 2024 04:02 PM ET
After-Market: $104.26 +0.03 (0.03%) 6:52 PM ET
3-Hold of 5 3
B Value C Growth F Momentum C VGM
Zacks News
Pfizer (PFE) to Buy Seagen for $43B, Boost Cancer Portfolio
by Zacks Equity Research
Pfizer (PFE) is set to buy Seagen (SGEN) in a $43 billion deal. Seagen's key products focus on cancer treatment.
Here is What to Know Beyond Why Merck & Co., Inc. (MRK) is a Trending Stock
by Zacks Equity Research
Zacks.com users have recently been watching Merck (MRK) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Pharma Stock Roundup: LLY's Alzheimer's Study Setback, FDA Updates for SNY, MRK
by Kinjel Shah
FDA accepts Sanofi's (SNY) Dupixent sBLA. Lilly's (LLY) solanezumab fails to prevent Alzheimer's in a study.
Merck (MRK) Stock Moves -0.63%: What You Should Know
by Zacks Equity Research
In the latest trading session, Merck (MRK) closed at $107.60, marking a -0.63% move from the previous day.
Merck (MRK) Reports Detailed Data From PAH Study on Sotatercept
by Zacks Equity Research
Merck & Co. (MRK) announces detailed data from the phase III STELLAR study of sotatercept for the treatment of pulmonary arterial hypertension in adults.
Bristol Myers (BMY) Gets EU Nod for Anemia Drug Reblozyl
by Zacks Equity Research
Bristol Myers Squibb (BMY) gets full marketing authorization from the European Commission, for Reblozyl for anemia associated with non-transfusion-dependent beta thalassemia treatment drug in adult patients.
Zacks Value Investor Highlights: Merck, Coca-Cola, Coca-Cola Consolidated, American Express and Chevron
by Zacks Equity Research
Merck, Coca-Cola, Coca-Cola Consolidated, American Express and Chevron have been highlighted in this Value Investor article.
Merck (MRK) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Merck (MRK) closed at $106.88 in the latest trading session, marking a -0.12% move from the prior day.
Secrets of Great Long-Term Stock Investors
by Tracey Ryniec
Even Warren Buffett admits there's a lot of luck involved in investing.
Is Trending Stock Merck & Co., Inc. (MRK) a Buy Now?
by Zacks Equity Research
Merck (MRK) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Corcept's (CORT) Q4 Earnings and Revenues Miss Estimates
by Zacks Equity Research
Corcept Therapeutics' (CORT) fourth-quarter earnings and revenues lag estimates.
Iovance (IOVA) Q4 Earnings In Line With Estimates, Revenues Nil
by Zacks Equity Research
Iovance (IOVA) reports Q4 earnings in line with our estimates. Management is on track to complete the rolling BLA submission for lifileucel in melanoma before first-quarter 2023 ends.
Mirati's (MRTX) Q4 Loss Narrows, Krazati Records First Sales
by Zacks Equity Research
Mirati Therapeutics (MRTX) reports a narrower-than-expected Q4 loss and records first sales of Krazati. Stock rises in after-hours trading.
Seagen (SGEN) Likely to be Acquired by Pfizer Claims WSJ
by Zacks Equity Research
Seagen (SGEN) may be acquired by the large-cap pharma company Pfizer at a valuation of more than $30 billion, according to a Wall Street Journal article. Seagen's stock is up 17% in pre-market hours in response to the news.
Pharma Stock Roundup: FDA Updates for SNY, PFE & Others, EU Nod to AZN Cancer Combo
by Kinjel Shah
FDA approves Sanofi's (SNY) Altuviiio and grants a priority tag to Pfizer's (PFE) regulatory applications for pipeline candidates.
Stock Market News for Feb 24, 2023
by Zacks Equity Research
U.S. stock markets closed higher on Thursday after a choppy session.
Moderna (MRNA) Lags on Q4 Earnings, COVID Jab Sales Down Y/Y
by Zacks Equity Research
Moderna's (MRNA) fourth-quarter earnings and sales miss expectations. Management reiterates guidance to record a minimum of $5 billion from COVID vaccine sales in 2023.
Should You Invest in the VanEck Pharmaceutical ETF (PPH)?
by Zacks Equity Research
Sector ETF report for PPH
Is Most-Watched Stock Merck & Co., Inc. (MRK) Worth Betting on Now?
by Zacks Equity Research
Zacks.com users have recently been watching Merck (MRK) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Merck (MRK) Gets Priority Tag for Antiviral Drug Prevymis sNDA
by Zacks Equity Research
The FDA grants priority review designation to Merck's (MRK) sNDA seeking expanded use of Prevymis. The PDUFA date is Jun 5, 2023.
Moderna (MRNA) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
Investors focus will likely be on Moderna's (MRNA) pipeline, especially with its late-stage pipeline candidates, when it reports fourth-quarter earnings.
Seagen's (SGEN) Q4 Earnings & Sales Beat Estimates, Stock Up
by Zacks Equity Research
Seagen (SGEN) reports better-than-expected results in the fourth quarter of 2022, beating both earnings and sales estimates. Stock up in the after-market hours in response to the news.
The Zacks Analyst Blog Highlights Merck, Thermo Fisher Scientific, American Express, Valero Energy and Weyerhaeuser
by Zacks Equity Research
Merck, Thermo Fisher Scientific, American Express, Valero Energy and Weyerhaeuser are part of the Zacks top Analyst Blog.
Top Stock Reports for Merck, Thermo Fisher Scientific & American Express
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Merck & Co., Inc. (MRK), Thermo Fisher Scientific Inc. (TMO) and American Express Company (AXP).
AstraZeneca (AZN) Q4 Earnings Beat, Sales Hurt by COVID Jab
by Zacks Equity Research
AstraZeneca (AZN) beats fourth-quarter estimates for earnings while missing the same for sales.